Insider Selling: Cellebrite DI (NASDAQ:CLBT) Insider Sells $285,625.71 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) insider Thomas Hogan sold 25,299 shares of Cellebrite DI stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the completion of the sale, the insider owned 765,249 shares in the company, valued at approximately $8,639,661.21. This trade represents a 3.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cellebrite DI Trading Down 2.4%

Shares of Cellebrite DI stock opened at $11.99 on Friday. Cellebrite DI Ltd. has a 12-month low of $9.58 and a 12-month high of $19.98. The company has a market cap of $2.99 billion, a P/E ratio of 54.50, a PEG ratio of 1.84 and a beta of 1.18. The company’s fifty day simple moving average is $14.16 and its two-hundred day simple moving average is $13.77.

Analysts Set New Price Targets

CLBT has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Lake Street Capital cut their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings downgraded Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday. DA Davidson lowered their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Needham & Company LLC dropped their price target on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.70.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors have recently modified their holdings of CLBT. Roubaix Capital LLC boosted its stake in Cellebrite DI by 108.1% in the 1st quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock worth $4,178,000 after purchasing an additional 157,536 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Cellebrite DI during the 1st quarter valued at about $2,134,000. Principal Financial Group Inc. increased its stake in Cellebrite DI by 33.9% during the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after purchasing an additional 545,334 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Cellebrite DI by 14.7% in the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after buying an additional 365,700 shares during the last quarter. Finally, Weiss Asset Management LP lifted its stake in shares of Cellebrite DI by 3,485.3% in the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after buying an additional 1,846,851 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.